Migraine treatment

BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine

Retrieved on: 
Wednesday, August 4, 2021
Migraine, Triptans, Drugs, Migraine treatment, Prevention of migraines

RALEIGH, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced today that it entered into an agreement on August 3, 2021 with Dr. Reddy’s Laboratories Limited to acquire the U.S. and Canadian rights to ELYXYB (celecoxib oral solution), the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.

Key Points: 
  • In pivotal studies, ELYXYB demonstrated a rapid onset of action which is critically important to patients suffering from acute migraine attacks.
  • The results from pivotal studies established the efficacy of ELYXYB in the treatment of acute migraine.
  • ELYXYBs unit-dose oral solution makes it convenient for patients to take it immediately upon emergence of acute migraine attacks.
  • We believe that this profile, coupled with the ready-to-use oral solution, make ELYXYB an attractive option for the acute treatment of migraine in adults.

Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

Retrieved on: 
Wednesday, July 28, 2021
Migraine, Medical research, Health sciences, Drugs, Migraine treatment, Clinical research, Drug discovery, Pharmaceutical industry, Prevention of migraines

(Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine.

Key Points: 
  • (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine.
  • The SUMMIT study was designed in accordance with FDA recommendations outlined in the FDA Guidance Migraine: Developing Drugs for Acute Treatment, February 2018.
  • For further information regarding the STS101 SUMMIT Phase 3 efficacy trial, see www.ClinicalTrials.gov, identifier NCT04940390: A Randomized, Double-Blind, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine (SUMMIT).
  • Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine.

electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones

Retrieved on: 
Tuesday, July 27, 2021
Headaches, Medicine, Branches of biology, Symptoms and signs, Pain management, Neurological disorders, Migraine, Cluster headache, Headache, ElectroCore, Electrotherapy, Migraine treatment

11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.

Key Points: 
  • 11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.
  • One or more electrodes apply electrical impulses through the patient's skin modulating a targeted nerve to treat the medical condition.
  • This newly allowed patent is owned by electroCore and is the latest U.S. patent to issue in connection with the companys non-invasive development program for pain.
  • The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

electroCore to Announce Second Quarter 2021 Financial Results on Thursday, August 5th

Retrieved on: 
Thursday, July 22, 2021
Medicine, Clinical medicine, Branches of biology, Headaches, Pain management, Migraine, Cluster headache, ElectroCore, Vagus nerve stimulation, Headache, Peter Staats, Migraine treatment

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.

Key Points: 
  • electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.
  • The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

The Journal of the American Medical Association Publishes Data on Efficacy and Safety of Preventive Migraine Treatment VYEPTI® (eptinezumab-jjmr) When Administered During an Active Migraine Attack

Retrieved on: 
Tuesday, June 15, 2021
Cardiology, Biotechnology, FDA, Other Health, Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical trials, Migraine, Monoclonal antibodies, Eptinezumab, Clinical medicine, Medical specialties, Health care, Prevention of migraines, Migraine treatment, the RELIEF Study Publication in JAMA, VYEPTI®, Migraine, Lundbeck, THE RELIEF STUDY PUBLICATION IN JAMA, VYEPTI®, MIGRAINE, LUNDBECK

The RELIEF study evaluated how preventive migraine candidates may benefit from a VYEPTI infusion during an active migraine attack when administered within 1 to 6 hours of a moderate to severe migraine attack.

Key Points: 
  • The RELIEF study evaluated how preventive migraine candidates may benefit from a VYEPTI infusion during an active migraine attack when administered within 1 to 6 hours of a moderate to severe migraine attack.
  • VYEPTI is the first and only intravenous (IV) infusion approved for the preventive treatment of migraine in adults.
  • Furthermore, an active migraine would not be an obstacle for initiating preventive treatment with VYEPTI.
  • The exploratory endpoint of time to next migraine was met (10 days with VYEPTI vs. 5 days with placebo).

Nerivio® Wins 2021 Medical Design Excellence Award

Retrieved on: 
Tuesday, June 1, 2021
Migraine, Migraine treatment, Digital therapeutics, Health

NETANYA, Israel, June 1, 2021 /PRNewswire/ -- Theranica , a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that its FDA-approved acute migraine treatment wearable Nerivio has been named a silver winner of the 2021 Medical Design Excellence Awards (MDEA)in the Digital Health Products and Mobile Medical Apps category.

Key Points: 
  • NETANYA, Israel, June 1, 2021 /PRNewswire/ -- Theranica , a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that its FDA-approved acute migraine treatment wearable Nerivio has been named a silver winner of the 2021 Medical Design Excellence Awards (MDEA)in the Digital Health Products and Mobile Medical Apps category.
  • The MDEA, organized by Informa Markets Engineering, is an award program dedicated to recognizing cutting-edge achievements in medical product design and celebrating the industry's foremost manufacturers designing groundbreaking medical devices that are changing patient care worldwide.
  • "We are honored to be recognized by the Medical Design Excellence Awards for the advanced technology behind Nerivio.
  • "Nerivio is advancing the migraine treatment market by expanding the options beyond medication a long awaited shift in the field.

2021 Market Report on Migraines - Epidemiology Forecast to 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 26, 2021
Health, Other Health, Migraine, Nervous system, Migraine treatment, Organ systems

The "Global Migraine Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Migraine Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides Migraine epidemiology, demographics, and patient flow.
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.
  • Demographics: Migraine patients by age group, gender
    The data from this research will help executives:
    Establish basis for Migraine market sizing, assessing market potential, and developing drug forecast models
    Identify Migraine patients segments through age groups, gender, and disease sub-types

electroCore to Announce First Quarter 2021 Financial Results on Thursday, May 6

Retrieved on: 
Thursday, April 29, 2021
Medicine, Clinical medicine, Branches of biology, Headaches, Pain management, Migraine, Cluster headache, ElectroCore, Vagus nerve stimulation, Headache, Peter Staats, Migraine treatment

b"electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.

Key Points: 
  • b"electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.
  • The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.\n"

AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine

Retrieved on: 
Monday, March 8, 2021
Migraine, Symptoms and signs, Clinical medicine, Branches of biology, Botulinum toxin, Headache, Migraine treatment, Prevention of migraines

Chronic migraine is a sub-type of migraine that is characterized by 15 or more headache days a month.

Key Points: 
  • Chronic migraine is a sub-type of migraine that is characterized by 15 or more headache days a month.
  • The Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month.
  • All patients will receive two treatment cycles utilizing the Companys novel treatment paradigm involving fewer injections than the current botulinum toxin treatment option for chronic migraine.
  • AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions.

Relivion® Wearable Brain Neuromodulation Technology Cleared by FDA for the Treatment of Migraine

Retrieved on: 
Tuesday, March 2, 2021
Health, FDA, Medical devices, Other Health, General Health, Clinical trials, Biotechnology, Branches of biology, Neuroscience, Neurotechnology, Neurological disorders, Neurophysiology, Migraine, Neuromodulation, Placebo, Migraine treatment, Prevention of migraines

Relivion is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits annually.

Key Points: 
  • Relivion is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits annually.
  • This allows for the release of neurotransmitters in the brainstem and modulation of brain networks associated with control of pain.
  • The FDA marketing clearance is based on the results of a multi-center, prospective, randomized, double-blind, placebo-controlled clinical study.
  • Neuroliefs technology is currently being utilized for patients with migraine and being studied for patients with major depression.